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Adoptive cell transfer therapy (ACT) is one of the most promising 
immunotherapies against cancer. However, this treatment regimen requires the 
expansion of a small population of effector cells, known as tumor infiltrating 
lymphocytes, into the billions in order to overcome the immunosuppressive tumor 
microenvironment. The cytotoxic T lymphocytes (CTLs) within this invading 
immune cell population are the most critical components to kill the growing cancer 
cells. Nonetheless, the rapid expansion of already exhausted tumor-infiltrating 
cytotoxic T lymphocytes (TICTLs) may further push them to a terminally 
differentiated state that reduces their proliferative response upon antigen stimulation. 
Recently, induced pluripotent stem cells (iPSCs) generated from TICTLs have been 
suggested as a way to create a renewable source of rejuvenated tumor-specific CTLs, 
but retroviral reprogramming is inefficient, and can lead to an increased chance of 
tumorigenesis. To improve the expansion of TICTLs, we used transient protein 
  
exposure to SOX2, OCT4, and NANOG (SON) in order to push these exhausted 
TICTLs to a less differentiated stage, preferably stem cell-like memory CTLs (Tscm). 
These three transcription factors were transiently delivered using a nuclear protein 
delivery system. We found only the TICTLs treated with SON (STICTLs) exhibited 
an increased proliferation rate and extended survivability, independent of additional 
cytokines and antigen stimulation both in vitro and in vivo; effector CTLs did not 
respond to the SON regimen. These highly proliferative STICTLs could be associated 
with up regulation of certain genes related in cell cycle control, such as cyclin D1. 
Though these STICTLs still express a T cell receptor (TCR), as well as many critical 
downstream components, they were unable to elicit a reaction against antigen 
exposure. Though clearly not iPSCs, it is possible that the SON treatment had pushed 
the TICTLs into a state similar to an early double negative thymocyte. Our findings 
indicate that TICTLs are uniquely responsive to protein SON compared to naïve and 
effector CTLs; suggesting TICTLs may also be sensitive to regulation by other more 
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Chapter 1: Introduction 
Cancer and the immunosuppressive microenvironment 
Cancer kills over 500,000 people each year, making it the second most 
common cause of death in the United States [1, 2]. In 2015 alone, an estimated 1.6 
million people will be diagnosed with cancer [2]. Each cancerous cell originates from 
a normal cell that has mutated to grow indefinitely [3]. As the complex processes of 
cancer formation and growth are being elucidated, the treatment options are slowly 
shifting from nonspecific and potentially toxic treatments, such as radiation and 
chemotherapy, toward immune-based options that specifically target the tumor [4, 5]. 
Immunotherapy has the potential to provide long lasting remission because of its 
specificity against the cancer cells, the capacity for memory formation, and a 
reduction in adverse events [6-9]. In order to develop effective therapies to control the 
cancer, we must first understand the interactions between the immune system and the 
tumor cells. 
 According to the Immunoediting Hypothesis, cancerous cells are only able to 
develop into a tumor if they are able to evade the attacks from the immune system [7, 
9-11]. There are two sides of the immune interface with cancer: anti-tumor and pro-
tumor. Although other immune cells, such as natural killer cells, can aid in the battle 
against cancer, the anti-tumor response is mainly administered by cytotoxic T 
lymphocytes (CTLs) (Figure 1). CTLs are characterized by their surface expression of 





cancer antigen [12, 16]. Naïve CTLs are antigen-inexperienced T lymphocytes that 
require activation by an antigen-presenting cell (APC), such as a dendritic cell (DC). 
Upon presentation of the correct antigen, the naïve CTL will proliferate and 
differentiate into an army of effector CTLs [12, 16, 17]. Three signals (3SI) must be 
present in order to fully activate these lymphocytes: antigen, costimulation, and a 
cytokine signal [18, 19]. On the surface of the antigen presenting cell, the antigen is 
presented on the major histocompatibility complex (MHC) class I, along with 
costimulatory surface molecules, like B7.1 and B7.2, providing the first and second 
activation signals [16, 19]. The third signal of activation is an inflammatory cytokine, 
such as IL-12 or Type I IFN [18-21]. IL-12 is produced by macrophages, B cells, and 
dendritic cells in the surrounding environment [22]. Without costimulation or a 
cytokine signal, the resulting T cells will most likely become tolerant [18, 23]. When 
CTLs are tolerant of a particular antigen, they no longer mount an effector response 
to kill their target. However, with proper stimulation from these three signals, the 
naïve CTL rapidly proliferates and differentiates into effector CTLs. These effector 
CTLs then infiltrate the tumor, prepared to bind and kill the cancer cells [13, 14, 24, 
25].  
However, the pro-tumor aspect of immune system is cultivated from within 
the tumor microenvironment. The cancer takes advantage of previously established 
immune checkpoints and inhibitory mechanisms to evade and tolerize the immune 
system [26]. The cancer cells begin by secreting suppressive factors like VEGF, IL-
10, TGF-β, and gangliosides [27-31]. These suppressive factors recruit myeloid-





dendritic cells, and regulatory T cells (Tregs) to the tumor and then enhance the 
regulatory component of their normal function [28, 31-34]. Though all of these 
different cell types are known to contribute to the inhibition of an anti-tumor 
response, the exact mechanism of how this suppression occurs is still under extensive 
investigation. 
These pro-tumor cells use a variety of strategies both at the site of T cell 
activation in the secondary lymphoid tissue and within the tumor itself. It begins at 
the level of antigen presentation. Immature dendritic cells are peripheral immune cells 
that promote self-tolerance [35, 36]. Under cancer conditions, these immature 
dendritic cells are fostered within the tumor by the excessive amounts of suppressive 
factors that inhibits dendritic cell differentiation and maturation [37]. IL -10 nudges 
the dendritic cells to express the co-inhibitory molecules PD-L1 (B7-H1) and B7-H4 
rather that the costimulatory molecules B7.1 and B7.2 [26]. B7-H1 molecules bind to 
the suppressive receptor PD-1 on T cells, directly suppressing T cell activation [38]. 
Without the proper signals at activation, the naïve CTLs are unable to adequately 
differentiate and expand, and may become tolerant. 
Already at a disadvantage, the anti-tumor response faces greater immune 
suppression within the tumor itself. Tumor-associated macrophages (TAMs) promote 
angiogenesis and these new blood vessels supply a steady amount of oxygen and 
nutrients to the cancer cells [3, 39]. In addition to this, tumor-associated macrophages 
also secrete anti-inflammatory signals such as IL-10, TGF-β, and arginase-1 [39, 40]. 
TGF-β secretion lessens the adaptive immune response in a few different ways [39]. 





dendritic cells [39].  TGF-β also directly inhibits natural killer cell and CTL anti-
tumor activity within the tumor [39]. IL-10 suppresses the production of pro-
inflammatory cytokines IFN-γ and IL-12 that encourage T cell differentiation, further 
reducing CTL anti-tumor activity [39]. Both tumor-associated macrophages and 
myeloid-derived suppressor cells expressed the inhibitory B7 homologs, PD-L1 (B7-
H1) and PD-L2 (B7-DC) as well as the costimulatory versions B7.1 and B7.2. PD-L1 
and PD-L2 bind to their receptor, programmed cell death protein 1 (PD-1). The 
costimulatory B7.1 and B7.2 can bind to cytotoxic T lymphocyte antigen 4 (CTLA4) 
instead of CD28. Both PD-1 and CTLA4 directly inhibit TCR signaling and thus anti-
tumor activity. 
 Myeloid-derived suppressor cells are a heterogeneous cell population of 
immature and mature myeloid cells, dendritic cells, activated granulocytes, and 
macrophages [26, 34, 41, 42]. These myeloid-derived suppressor cells are able 
contribute to the suppressive environment within the tumor in a variety of ways [26, 
34, 41, 42]. In addition to the mechanisms mentioned above,  myeloid-derived 
suppressor cells produce reactive oxygen and reactive nitrogen species using 
inducible NO synthase and NADPH oxidase [39, 41, 43, 44]. These reactive species 
further suppress T cell proliferation and limiting their reaction against the tumor [39, 
41, 43, 44].  Myeloid-derived suppressor cell’s expression of the inhibitory molecule 
CTLA4 also helps promote differentiation of regulatory T cells [45]. 
Another strategy these cells use to promote tolerance of the tumor is through 
the reduction of essential amino acids in the local environment. The  myeloid-derived 





amino acids in the local environment [39, 44, 46-49]. The depletion of L-arginine by 
arginase-1 especially impairs T cell proliferation and cytokine production, thus 
promoting T cell anergy [47]. Anergy is a state of tolerance T cells acquire after being 
exposed to their antigen [50]. The upregulated expression of indoleamine 2,3-
dioxygenase (IDO) on the surface of myeloid-derived suppressor cells and immature 
dendritic cells also aids in the depletion of essential amino acids, because IDO is an 
enzyme that degrades tryptophan [51]. This elevated expression of IDO has been 
linked to an increased infiltration of regulatory T cells [48].  
The regulatory T cells that infiltrate the tumor further incite the 
immunosuppression [52-54]. Under normal circumstances, regulatory T cells act to 
maintain tolerance of self-antigens and to reduce inflammatory responses after a 
challenge. Within the tumor, regulatory T cells use anti-inflammatory cytokines and 
cell-to-cell contact to reduce the anti-tumor response. The detailed mechanism by 
which regulatory T cells directly induce cell tolerance is still a major topic of research 
[55]. Regardless, it is clear that Tregs assist with the suppression of the pro-
inflammatory reaction. Like the surrounding tumor cells and tumor-associated 
macrophages, regulatory T cells produce IL-10 and TGF-β [52, 56]. They also 
constitutively express CTLA4, the inhibitory receptor that bind to B7 costimulatory 
molecules expressed on antigen presenting cells, thus impairing activation of anti-
tumor CTLs. These attributes contribute to the regulatory T cells ability to inhibit the 
immune’s effector response.  
Once the effector CTLs have entered the tumor microenvironment, all of these 





the tumor. The regulatory T cells can directly bind to the TICTLs, while myeloid-
derived suppressor cells, immature DCs, and tumor associated macrophages work 
with cancer cells to establish the immunosuppressive microenvironment with signals 
like IL-10, TGF-β (Figure 1). The combined effect of these pro-tumor immune 
mechanisms prevents the TICTLs from eliciting an effector response sufficient to 
control tumor growth. These confused tumor-infiltrating CTLs (TICTLs) take on an 
increasingly exhausted state, and remain within the tumor [57, 58]. The tolerance 
created in this environment is one of the biggest obstacles for controlling the cancer 





















Figure 1: A look inside the tumor. A representation of how the pro-tumor immune 
cells and cancer cells act on the anti-tumor effector cells to prevent the effector CTLs 













Nonspecific immune therapies 
The mimicry of immunological tolerance mechanisms has given new targets 
to non-specific cancer immunotherapies [10]. Ipilimumab and nivolumab are 
monoclonal antibodies that bind to CTLA4 and PD-1 respectively [9, 10]. Ipilimumab 
blocks CTLA4 from being activated thus allows the T cell anti-tumor activity to 
continue [10, 66-68]. So far ipilimumab has been approved for use against melanoma 
and is currently in clinical trials against non-small cell lung cancer (NCT00527735), 
bladder cancer (NCT01524991), and prostate cancer (NCT00323882) [69, 70]. 
Though melanoma patients treated with ipilimumab showed an increased overall 
response rate of 10.9% and overall survival rate of 47.3%, the unlimited proliferation 
of T cells also increased the risk of adverse events related to an overactive immune 
system [70, 71]. Nivolumab targets PD-1, another inhibitory receptor expressed on 
the surface of activated T cells [38, 66]. As mentioned above, when PD-1 binds to 
one of its ligand PD-L1 or PD-L2, the T cells’ effector function is down-regulated 
[72]. Nivolumab competitively inhibits PD-1 and prevents its activation, resulting in 
an increase in T cell effector function and a clear tumor regression in 31% of patients 
[38, 73]. The toxicity of this therapy appears to less than that of other immune 
therapies like IL-2 supplementations and ipilimumab [69]. In addition to melanoma, 
nivolumab has been approved for lung cancer and is currently in clinical trials for 
other forms of cancer including leukemia (NCT02420912), renal cell carcinoma 
(NCT01472081) [74]. Many of these clinical trials are also investigating the use of 
these inhibitors in conjuncture with other treatment options including each other 





cancer establishes in the CTLs by blocking PD-1 and CTLA4. But the tumor cells can 
use other immunosuppressive mechanisms to inhibit the anti-tumor response of 
TICTLs. 
The supplementation with certain cytokines can help stimulate the immune 
response. The cytokine interleukin-2 (IL-2) is a survival signal used to promote the 
proliferation and cytolytic action of T cells [75, 76]. IL-2, also known as Aldesleukin, 
was the pioneering immunotherapy to elicit a reduction in tumor size [77]. Approved 
by the FDA in 1998, IL-2 was able to show durable response rates against metastatic 
cancers, like melanoma and renal cancer, in about 15-20% of patients when a high 
dose of either 600,000 or 720,000 Units/kg were administered every 8hrs for 14-15 
consecutive doses [76, 77]. Despite this positive tumor response, IL-2 has also been 
linked to increased regulatory T cell activity, which countermands the pro-
inflammatory, anti-tumor response that we hope to incite [58, 75, 78]. In more recent 
years, IL-2 has been combined with other forms of immunotherapy, like adoptive cell 
transfer therapy, ipilimumab (NCT01856023), and BCG vaccination, to develop a 
more effective regimen to deliver long lasting remission [77, 79]. While all of these 
treatment options have shown to have an effect on the immune response’s ability to 
slow the progression of the cancer, the cancer still continues to evade and grow. More 
targeted treatment options, such as antigen specific immunotherapies, may prove to 
be more effective in halting the advancement of the cancer. 
Cancer vaccination 
Many cancer-specific antigens have been identified in a variety of cancers that 





However, so far all attempts at developing a cancer-specific vaccine that is capable of 
producing a clear tumor response on its own has failed. Some of the cancer vaccines 
made it through phase I and phase II clinical trials before disappointing results, 
preventing them from continuing into phase III clinical trials. Cancer vaccination 
approaches are divided into three categories: peptide or protein vaccines, dendritic 
cell vaccines, and whole tumor cell vaccination. In peptide vaccines, a known cancer 
antigen, like gp100, is isolated and injected into the patient with an adjuvant to 
attempt to increase the immune response against that antigen [81]. In the case of the 
gp100 cancer vaccine, there was not a significant difference in survival or tumor 
regression in metastatic melanoma patients when the gp100 vaccine was used alone, 
but there was improved survival when administered with high dose IL-2 [82]. This 
vaccine is now used as a control for other clinical trials [71, 83-85] 
Another option, known as dendritic cell vaccination, loads peptides from 
melanoma antigens onto CD34+ dendritic cells [82, 86]. After immunization with 
these loaded dendritic cells, the overall survival increased by 2 years, though there 
was no change in the tumor [82, 87]. The last common vaccination procedure is 
whole-tumor cell vaccination [82]. This is the classic method of immunization using 
whole irradiated tumors allows for exposure to a broader spectrum of the cancer-
associated antigens [82]. This method showed an 8.1% clinical response compared to 
3.6% response for immunization with synthetic peptides in phase I clinical trial [82, 
88]. The problem with fighting cancer is not just antigen exposure. Vaccinations do 





immune system, and this could be the main reason why a therapeutic vaccination 
against melanoma has been ineffective so far. 
Antibody-based therapies against cancer-specific antigens can be very 
therapeutically relevant. One example of these specific antibody therapies is 
Vemurafenib. Vemurafenib is a monoclonal antibody based therapy that targets the 
mutated B-raf enzyme (BRAF) associated with 40-60% of melanoma [9, 66]. The 
antibody essentially tags the cells expressing the appropriate antigen, like BRAF, 
making them easier targets for immune response to destroy [16, 89, 90]. Phase I and 
Phase II clinical studies have shown that there is a 53-57% response rate in patients 
with melanoma containing the BRAF V600E mutation [89, 91]. The development of 
more monoclonal antibodies for tumor specific antigens will be helpful to increase the 
response against the tumor, but the response against the tumor is fleeting. In the case 
of BRAF V600E, the cancer can quickly become resistant to this method of 
treatment. The cancer cells respond to anti-BRAF treatment by bypassing the reliance 
on BRAF by indirectly activating the same RAS-RAF-MEK-ERK survival pathway 
using the BRAF alternative, CRAF, to continue to survive [92, 93]. Though further 
investigation is required to understand exactly what mechanism is responsible for the 
development of this resistance, it is clear that the intense selective pressure that 
produces such a strong initial response rate also selects for mutations that allow the 
cancer to resist in the future [94-96]. Rather than focus on the short-lived humoral 
approaches, immunotherapies based on the cellular part of the adaptive immune 






Adoptive cell transfer therapy 
Among the more successful treatment options is adoptive cell transfer therapy 
(ACT). ACT utilizes activated T lymphocytes that have infiltrated the tumor (TILs) to 
control the cancer by removing TILs from the immune suppressive tumor 
microenvironment, expanding them in vitro, then infusing these cells back into the 
patient to attack the tumor [97-102]. In both the in vitro and in vivo aspects of ACT, 
the survival signal Interleukin-2 (IL-2) is used to promote the proliferation and 
cytolytic action of T cells [8, 103].  
The standard protocol begins with the surgical excision of the tumor [103]. 
The patient is then given lymphodepleting chemotherapy, while the TILs are then 
expanded in vitro from either a small chunk of the tumor or single cell suspension of 
digested tumor in a 24-well plate for 1-2weeks [81, 103]. When roughly 1.5x106 cells 
are present in each well, it was split into 2 daughter wells [81, 103]. The fastest 
growing cultures undergo the rapid expansion protocol [103]. Under this protocol, 
these cells were co-cultured with anti-CD3, IL-2, and irradiated peripheral blood 
monocyte feeder cells for 14 days [100, 103-106]. These irradiated peripheral blood 
monocytes are non-dividing cells that present tumor antigens to the lymphocytes with 
which they are co-cultured [103, 104, 107, 108]. The TILs are then infused back into 
the patient when the expanded cell number is greater than 3.1x1010 and up to 1x1011 
cells [85, 103, 109, 110]. The patient also is administered a high dose of IL-2 
(720,000 IU/kg) every 8 hours after TIL injection fro 2-3 days [8, 104]. This standard 






Limitations of ACT 
Despite this promising response rate, ACT has considerable limitations in a 
clinical setting and in efficiently activating TILs. IL-2 often causes additional clinical 
complications, such as capillary leak syndrome, hypotension, and pulmonary failure 
[111, 112]. IL-2 has also been linked to increased regulatory T cell activity and may 
contribute to further immune suppression of CD8+ T cells by regulatory T cells [63]. 
While it is recognized that cytolytic T lymphocytes (CD8+ T cells) are the most 
effective cancer killing cells, the expansion these already exhausted TICTLs must 
undergo to meet the high cell number requirement (3.1x1010-1x1011 cells) for transfer 
could be pushing them to a terminally differentiated state  [6, 113]. This push to an 
older more terminal state impairs proliferative ability, which in turn reduces the 
TICTL’s ability to respond to the cancer [57, 60, 113, 114].  
A few clinical trials are underway to overcome many of limitations associated 
with ACT. Some are looking into the interaction between ACT and other commonly 
used therapies to see if there is an improved clearance of the cancer. In addition to 
trials that are attempting to optimize the chemotherapy lymphodepletion regimen 
(NCT01807182, NCT01993719), other trials are combining drugs that target cancer-
related pathways with ACT.  An ongoing clinical trial is evaluating the safety of 
vemurafenib when used in conjuncture with ACT (NCT01585415) [84]. A more 
effective treatment regimen that reinvigorates the exhausted T cells could be 
developed to help overcome the tumor immune suppression.  
Another approach to over coming ACT’s limitations is focused on developing 





specificity. Ideally, these engineered receptors would target tumor-associated antigens 
that are express on the surface of all cancer cells, including cancer stem cells, but not 
on other tissues [115, 116]. Unfortunately, the antigens commonly expressed on the 
cancer are rarely perfect targets. Many of the antigens cancer expresses are derived 
from normal genes that have been subject to point mutations that lead to an altered 
epitope [117]. Costimulatory signals are added to each of the CARs to enhance 
activation [115, 118, 119]. This method does not require the lymphocyte to be 
naturally specific for the target antigen. Instead, the lymphocytes used in these trials 
are often purified from the peripheral blood, not the tumor. These lymphocytes are 
then retrovirally transduced with the CAR, expanded and injected back into the 
patient with a high dose of IL-2. Engineering the TCR and inserting it into a 
harvested lymphocyte can achieve cancer antigen specificity without pushing the cells 
to their terminally differentiated state.  
So far effective CARs for surface cancer antigens MART-1, anti-VEGFR2, 
anti-CD19, and anti-GD2 are in phase I or phase II clinical trials (NCT00910650, 
NCT01218867) [120, 121]. There are many other ongoing clinical trials looking at 
the effectiveness and safety of anti-GD2 (NCT02107963, NCT01822652), and anti-
CD19 (NCT02349698) against a variety of different cancer types including 
melanoma and lymphoma. In some cases, the adoptive transfer of the CAR 
possessing T cells has increased the response rate to 66% or higher [119]. Even 
though the number of lymphocytes able to infiltrate the tumor does not limit this 
method, CAR T cells still are only reactive on one particular cancer antigen. This 





providing a selective pressure for the cancer to develop without the expression of that 
antigen. If the TCR diversity of wildtype TICTLs can be preserved and the cell 
number of this heterogeneous population increased without exhausting these cells, 

















Figure 2: Progression of CTL Differentiation. Schematic of CTLs from least 














Memory CTL subsets 
Rather than continuing to push the T cells to a terminally differentiated state, 
ACT may benefit if the protocol promoted the formation of less differentiated CTL 
phenotypes, such as stem cell-like memory CTLs or central memory CTLs (Figure 2). 
A less differentiated cell is able to mount a more intense effector response when faced 
with an antigenic challenge. Antigen experienced memory CTLs are divided into 
subtypes capable to responding more vigorously when exposed to an antigen than a 
naïve CTL [113, 122, 123]. All memory subsets have the capability of maintaining a 
homeostatic population over a long period of time and differentiating into effector 
CTLs upon antigen reoccurrence [16, 124, 125]. Central memory T cells tend to be 
found in the peripheral lymphatic system, with a phenotype of IL-7Rhi, CD62Lhi, 
CCR7hi and have a substantial proliferative response to the antigen [123, 126, 127]. 
Stem cell-like memory CTLs (Tscm cells) are the least differentiated memory subtype 
and have the capability of differentiating into central memory CTLs, and effector 
memory CTLs as well as effector CTLs [128]. This unique capacity of Tscm cells to 
differentiate into other memory subsets as well as effector CTLs gives these cells a 
more pronounced proliferative response to an antigen [128]. By focusing on this 
particular Tscm cells phenotype, high cell transfer number necessary for ACT may be 
reduced and the effector response increased [126]. 
Tscm cells were first discovered through WNT signal activation with the 
GSK3B inhibitor TWS119 [128, 129]. Since Tscm cells were discovered, the 
recognized phenotype CCR7+, CD62L+, CD27+, CD28+ and IL-7Ra+ has been used 





humans and mice [128, 130, 131]. Unfortunately, this memory phenotype makes up a 
very small percentage of the memory cell population in the body [122, 129, 132]. In 
vitro, only a limited number of these cells can be generated through WNT signal 
activation possibly because WNT signaling may inhibit CTL activation [122, 129, 
132]. A protocol to efficiently generate Tscm cells needs to be developed so these 
reactive cells can be used in a clinical setting.  
Reprogramming to iPSCs 
While the insertion of a genetically engineered chimeric antigen receptor is a 
popular approach to reduce the limitations of adoptive cell transfers, using 
regenerative techniques may prove to be more effective in providing younger 
effectors against the malignant cancer [133, 134]. By reprogramming these exhausted 
TILs back to induced pluripotent stem cell, the TILs can be guided into a younger, 
less differentiated state that can provide a stronger proliferative and effector response 
when encountering the antigen (Figure 3) [113, 128]. Reprogramming usually refers 
to the retroviral insertion of transcription factors that are used to push a fully 
differentiated somatic cell into a pluripotent state creating an induced pluripotent 
stem cell (iPSC) [135-137]. Traditionally, the Yamanaka factors OCT4, SOX2, Klf-4, 
and C-MYC (OSKM) are used, but by using SOX2, OCT4, and NANOG and 
removing the proto-oncogenes KLF4 and C-MYC, it may be possible to reduce 
oncogenic mutation rates [137-139].  
SOX2, OCT4, and NANOG (SON) are known master controlling 
transcription factors of reprogramming [140]. In embryonic stem cells, the expression 





or guide differentiation [140]. These SON transcription factors act upon a complex 
network of signaling pathways during early embryonic development, including the 
WNT signaling pathway [140, 141]. When overexpressed in somatic cells, they guide 
the cells back to a pluripotent state and create induced pluripotent stem cells [142]. 
While the specific mechanism of action of SON in immune cells is unclear, these 
transcription factors have been used successfully to reprogram mature T cells into an 
induced pluripotent stem cell [143]. SOX2 and NANOG are normally expressed in 
only pluripotent embryonic and somatic stem cells and are not expressed in normal 
peripheral blood T cells [144-146]. The relationship between CTLs and OCT4 is a 
complicated one. Some CTLs even mount an immunological response against OCT4 
[147]. OCT4 has two main isoforms OCT4A and OCT4B. OCT4A is one of the main 
transcription factors responsible for embryonic stem cell (ESC) pluripotency [148]. 
OCT4B, on the other hand, is unable to sustain this state of self-renewal in ESCs, but 
seems to be related to cell stress [148]. The isoform OCT4B is expressed in 
peripheral blood mononuclear cells, including CTLs, but the expression of the 
pluripotency marker OCT4A is still contested [149, 150].  
An induced pluripotent stem cell has many of the same characteristics and 
capabilities of an embryonic stem cell including the ability to differentiate into 
endoderm, mesoderm, and ectoderm [135, 137]. These are the three tissues from 
which all of an organism’s cells are derived [135, 137]. Induced pluripotent stem cells 
express genes closer to that of an embryonic stem cell then a differentiated cell such 
as the fibroblast. These iPSCs are defined by their ability to form teratomas, a type of 





Retroviral reprogramming of a somatic cell into an induced pluripotent stem cell reduces number 
of ethical concerns that plague regenerative medicine when the generation of a 
specific cell type relies on harvesting human embryonic stem cells from embryos 
[137, 151]. The induction of pluripotency in somatic stem cells means that these cells 
can be guided toward many different cell fates. However, other studies have shown 
that these reprogrammed cells may still retain a sort of methylated memory of the 
original somatic cell’s chromatin structure [152-155]. While this epigenetic memory 
may cause problems if the cell needs to be reprogrammed to a different cell type, this 
preference for the original somatic cell type may work to the advantage of ACT [113, 
156]. 
T-iPSCs 
Previous attempts to reprogram T cells back to pluripotency to create iPSCs 
(T-iPSCs) then guided forward have shown that the T cells products of T-iPSCs 
retain their original TCR [113, 156]. This retention may allow these rejuvenated cells 
to maintain the naturally diverse reactive T cell population against a variety of 
different antigens the cancer may possess [113, 156]. Since the newly reformed T 
cells are no longer antigenically exhausted, these younger cells are able to elicit an 
enhanced effector response in addition to expressing their original TCR [113, 156].  
A common approach was to use the Sendai virus encoded with the Yamanaka 
factors SOX2, OCT4, C-MYC, and KLF4 [156, 157]. Generally, the CD3+ cells 
isolated from peripheral blood mononuclear cells of healthy humans were activated 
with anti-CD3/CD28 microbeads for 2 days before viral transduction could take place 





lymphocytes are transduced with the Sendai virus while in T cell media including IL-
7, IL-2, and IL-15 for 6 days before being reseeded onto mouse feeder fibroblasts. 
Once plated with these feeder cells, it takes as long as 40 days to form iPSCs from in 
vitro activated T cells (T-iPSCS) [156]. In order to reform functional, mature T cells, 
these T-iPSCs undergo a protocol that relies on a sequence of feeder cells with 
additional signals added to push the T cells through each stage of differentiation 
[156]. A final exposure to either anti-CD3 coated beads or PHA for activation 
preserved the original TCR and prevent TCRa rearrangement [156]. While this 
method did yield responsive, antigen specific CTLs, the generation of retroviral 
















Figure 3: Regenerative Techniques. Diagram of general differences between 



















Rather than pushing cells all the way back to a pluripotent state, lineage 
reprogramming, also known as transdifferentiation, directly reprograms somatic cells 
into either a precursor cell along the same developmental pathway or an entirely new 
somatic target cell (Figure 3) [160]. This shortens the generation time, because the 
somatic cell does not have to go through an induced pluripotent state. Two different 
approaches can be used to perform this lineage conversion. 
The first, retrovirally inserts transcription factors associated with the target 
cell type, then plates the cells under stem cell culturing conditions to promote the 
formation of the precursor [160]. The second, uses conventional reprogramming 
transcription factors and cultures the cells under conditions favorable for that target 
lineage [160]. The transduction of the reprogramming transcription factors can be 
delivered retrovirally or by using cell-penetrating peptides to deliver the genes to the 
nucleus [160].  
 By directly converting the cell from one type to another, these reprogramed 
cells have the shorter reprogramming protocol when compared to a somatic cell 
pushed back to pluripotency then guided to the target lineage [160]. Though this 
method has not been demonstrated yet in T cells, human fibroblasts have been 
successfully reprogrammed into hematopoietic progenitor cells using the lentiviral 
transduction of OCT4 and culture conditions optimized for the generation of 
hematopoietic progenitor cells [161]. In this case, human fibroblasts transduced with 





then CD45+ cells were transferred to media with hematopoietic cytokines (SCF, G-
CSF, FLT3LG, IL-3, IL-6, and BMP-4) for 16 days [161]. The cells were tested for a 
variety of cell markers for pluripotency, hematopoietic cells, and mesodermal cells 
[161]. Further research needs to done to elucidate if T cells are amenable to lineage 























Figure 4: T cell development in the thymus. Depiction of T cell development as it 
moves through the double negative (DN) stages, the double positive (DP) stage, and 





































Difficulties with lineage reprogramming 
One of the difficulties with lineage reprogramming using conventional 
transcription factors and specific culture conditions is pinpointing where along the 
lineage these cells have been reprogrammed [133, 160]. All blood cells, including 
CTLs, originally develop from hematopoietic stem cells in the bone marrow [16, 
162]. In the case of T cells, these hematopoietic stem cells then differentiate into 
multipotent stem cells and then into lymphoid progenitor cells [16, 162].  Lymphoid 
progenitor cells then differentiate into early thymic progenitors cells [16, 162].  These 
early thymic progenitor cells migrate from the bone marrow to the thymus [16, 162]. 
If the CTLs were pushed too far back along the lineage into these progenitor cell 
types, then the resulting phenotype would be unable to respond to antigen stimulation 
because precursor cells would lack the appropriate machinery to recognize an 
antigenic challenge.  
Once in the thymus, precursor T cells known as thymocytes undergo multiple 
rounds of TCR gene rearrangement (Figure 4) [16, 162, 163]. This random 
rearrangement with in the TCR genes is responsible for the T cell population’s ability 
to protect against a wide variety of antigens [16, 162, 163]. As the thymocytes 
matures, the cell acquired components of the cytolytic signaling pathway, but they do 
not possess a mature TCR capable of correctly identifying the target antigen until the 
last double negative stage and the double positive stage [16, 162, 163]. At this point, 
the thymocytes undergo selection processes to ensure each possesses a functional 
TCR and prevent the development of autoimmune diseases [16, 162, 163]. If the 





still be unable to respond to the antigen challenge because they do not possess the 
necessary costimulatory CD4 or CD8. Double positive cells may not possess a 
cytolytic ability. Neither of these thymocytes should exhibit the proliferative response 
and differentiation necessary to mount an attack against their target.   
The younger, less differentiated phenotypes that arise from mature single 
positive T cells after exposure to their associated antigen would be the best target for 
lineage reprogramming the TICTLs. The most optimal subset of T cells would be the 
Tscm because of their ability to differentiate into many other CTL phenotypes. But if 
the cells are not pushed back far enough along the T cell lineage, they may remain in 
a tolerant, unproliferative state that is prone to apoptosis. Characterization of the 
expression for phenotypic markers at each stage in development and differentiation is 
essential to determining if the lineage-reprogrammed cell was successfully 
transdifferentiated into the target cell type.  
Limitations of retroviral reprogramming 
The use of retroviral transduction to generation of T-iPSCs or to induce 
lineage reprogramming has many weaknesses when applying this method to a clinical 
setting. The genes responsible for inducing the pluripotent state in these somatic cells 
are inserted into the genome, permanently altering it. This retroviral insertion may 
lead to gene mutation and tumorigensis [160, 164, 165]. The reprogramming 
efficiency of human somatic cells is low and the method of reprogramming the cells 
is usually more than 3 weeks in length [135, 160]. Since cells derived from a tumor 
environment may need to undergo an expansion protocol before reprogramming, at 





transferred back into the patient. The lengthy protocol is not suited to the limited time 
most cancer patients have. The added risk of further mutation and generation of 
additional tumors reduces the appeal to patients already fighting against cancer. All of 
these concerns limit the application of retroviral reprogramming in a clinical setting 
[166].  
Alternative reprogramming techniques are being explored to improve the 
safety and reduce the reprogramming time of somatic cells including plasmid 
transfection and a variety of protein delivery systems. So far the efficiency of 
reprogramming with these techniques has been minimal [160].  
QQ-delivery 
However, a fairly new nuclear delivery system known as the QQ-protein 
transduction technique is showing promise in the generation of iPSCs without the use 
of a retroviral system [167]. This new protocol for creating iPSCs has emerged 
recently from Wayne State University using a nuclear localizing reagent known as 
QQ [167]. The patented QQ reagent delivers the recombinant proteins directly to the 
nucleus of the cell and remains therefor two days as shown by codelivery with GFP 
[167]. The nature of this delivery system ensures a controlled exposure to the 
reprogramming transcription factors long enough to generate piPSCs. The risk for 
mutation and tumorigenesis is reduced, because the genes for these reprograming 
factors are not inserted into the genome. Instead, these pluripotent inducing proteins 
are delivered to the nucleus. This protocol claims to generate piPSCs within a week 





regulators SOX2, OCT4, and NANOG (SON) [167].The patent also claims this 
technique using SON or OSKM has a near 100% efficiency of iPSC generation [167]. 
To generate iPSCs using this nuclear delivery system, the recombinant 
transcription factors were added to the QQ-reagent, then the somatic cells such as 
adult fibroblasts were treated using 24-hour cycles of QQ exposure for 3-12 hours 
followed by 21-12 hours of rest in QQ-free media [167]. In order to full reprogram 
somatic cells, they must undergo a minimum of 2-3 cycles of QQ-SON [167]. After 
5-7 days, 500-1500 piPSC colonies have formed [167]. This unique feeder-free 
protocol that utilizes the protein transcription factors claims to reduce many of the 
concerns retroviral transduction by decreasing the reprogramming time, increasing 
reprogramming efficiency, and eliminating the chance of retroviral mutation. It is 
possible that the QQ delivery system can be used to reprogram these tolerant tumor 
infiltrating T cells to a younger phenotype without reverting back to pluripotency by 
adapting this delivery system to lineage reprogramming. 
Combining lineage reprogramming and QQ-delivery 
Lineage reprogramming using an alternative to retroviral transduction may 
prove to be safer and more efficient if the QQ nuclear protein delivery system is used. 
In addition to reducing the concerns associated with retroviral transduction and 
showing a higher efficiency of transcription factor nuclear translocation, this system 
only requires a few days to push to full pluripotency and allows only a transient 
exposure to the reprogramming transcription factors, which will allow greater control 
when fine tuning the optimum exposure time to SON. That being said, this approach 





promote the target cell type. The culture conditions necessary to target specific 
phenotypes of CTLs using lineage reprogramming have yet to be elucidated. Utilizing 
conventional reprogramming transcription factors, SOX2, OCT4, and NANOG, and 
culturing the cells under T cell activation conditions is the best place to begin 
exploring T cell lineage reprograming. Under optimal in vitro activation conditions, 
naïve CTLs are primed to differentiate into effectors cells prepared to combat the 
antigen challenge and even capable of forming memory CTL [18, 19]. The SON 
transcription factors have successfully reprogramed exhausted T cells in retrovirus 
system, and have been used with the QQ nuclear protein delivery system [133, 167, 
168]. By creating the conditions that promote young CTLs while being stimulated 
with SON transcription factors will most likely encourage the lineage reprogramming 
toward a stem cell like memory CTLs. 
The need for a fast, efficient way to develop a large CTL population capable 
of reacting to a variety of cancer antigens is paramount in the war against cancer and 
may prove to be beneficial to adoptive cell transfer therapy. We want to investigate 
the first steps in optimizing the lineage reprogramming conditions necessary to 
produce a high number of younger CTLS, like stem cell-like memory CTLs, from 
exhausted tumor infiltrating CTLs. I hypothesis that treatment with SON under T cell 
activation conditions will yield highly proliferative, less differentiated CTL still 









Chapter 2: Methods 
Animal Model 
OT-I mice (gifted by Dr. Mescher, University of Minnesota) possess a transgenic 
TCR are specific for the H-2Kb OVA257-264 of the Ovalbumin protein. These 
transgenic mice also exhibit the same background genetics as C57BL/6 mice. 
C57BL/6 mice were purchased from NCI or Charles River Laboratories. All mice 
were housed under pathogen-free conditions at University of Maryland, College Park. 
All animal protocols were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) at University of Maryland (R-15-22).  
Cancer Model 
EG7-OVA cells were obtained from Dr. Mescher (University of Minnesota) and 
stored at -80C. To recover the cryogenic vials were thawed in 37OC water bath, then 
transferred to a 9ml of 25% FBS Allos medium and incubated at room temperature 
for 10minutes. The viability was checked with trypan blue before spinning down cells 
at room temperature and resuspended in 10ml of 25% FBS allos medium. G418 at 
200ug/ml was used to select for OVA expressing cells and the cells cultured in 37OC 
incubator with 5% CO2. 
 
TICTL generation and harvest 
OT-I mice were injected subcutaneously with 20x106 EG7-OVA257-264 cells per 200ul 
of DPBS. When the tumor reached 20mm in diameter, the mice were humanely 





with Collagenase D (400ug/ml), Hyaluronidase (2.5U/ml), and DNase (0.1mg/ml). 
Collagenase D was stopped with 0.1M EDTA after digestion. The cells were 
homogenized again into a single cell suspension before being washed with DPBS 
multiple times. Then the cells were resuspended in Allos media at 20million cells/ml 
and stained with 5ul CD8 PerCP/ml. The cells were then washed and resuspend at 
20million cells/ml of Allos. Using the FACSAria II flow cytometry machine, the 
tumor cell suspension was sorted according to CD8+ expression. Depending on how 
many CD8+ T cells were isolated from the tumor, between 5x105 or 1x106 CD8+ T 
cells were then plated per well in Allos media on a flat-bottom microtiter with or 
without SON stimulation. 
Naïve T cell purification 
Naïve OT-I CTLs were isolated from inguinal, axillary, brachial, cervical and 
mesenteric lymph nodes (LN) as previously reported [20]. Briefly summarized, the 
LNs were pooled and homogenized into a single cell suspension. Then CD8+ CD44lo 
cells were isolated using negative selection. Cells were labeled and incubated with 
FITC antibodies for CD4, B220, I-Ab, and CD44. These FITC labeled cells were 
incubated with Anti-FITC magnetic Microbeads (Miltenyi Biotech). The labeled cell 
suspension was then passed through separation columns on a MACS magnet. Cells 
that passed through the column were collected and displayed >95% CD8+ and <0.5% 







Cells received treatment using the QQ nuclear protein delivery technique (QQ-SON) 
from Dr. Jianjun Wang, Wayne State University (Patent #US20140242694 A1). QQ-
SON consists of the nucleus targeting QQ-reagent and recombinant protein 
transcription factors SOX2, OCT4, and NANOG (SON) that delivers these 
reprogramming proteins to the nucleus of somatic cells. For each 24hour cycle 
treatment, the Naïve CTLs or TICTLs were exposed to 5ul QQ-SON in 1.5ml total 
Allos media for 5 hours before changing the media to 1.5ml Allos media without QQ-
SON to allow the cells to rest for 19hours. When they are treated for 48hours they 
undergo two consecutive 24hour cycles as described above. After exposure to QQ-
SON, the cells were transferred to a well with the three signals necessary to activation 
naïve CTLs and 1.5mls of Allos. 
In vitro stimulation of CTLs  
Flat-bottom microtiter wells in 24-well plates were coated with recombinant B7-1/Fc 
chimeric protein (R&D Systems) for costimulation and the antigen OVA257-264 loaded 
onto DimerX H-2Kb:Ig fusion protein (BD Pharmingen) [20]. 2U/ml of murine rIL-
12 (R&D Systems) were added to each coated well making these wells stimulated 
with all three activation signals (3SI) and 2.5U/ml of IL-2 was added as a survival 
signal. For the first antigen exposure after QQ-SON treatment, the cells were 
stimulated with 3SI for 4-5 days and incubated at 37 OC and 5% CO2. For each 
additional exposure to antigen, 3x105 cells were stimulated for 3 days under 3SI 
conditions in 1.5ml of Allos media. All controls not treated with QQ-SON were 





1.5ml Allos media on uncoated wells without supplemental IL-2 or rIL-12 after the 
initial 4-5 day 3SI stimulation. Cells were identified with anti-CD45.2 mABs. 
Adoptive cell transfer  
In vitro cultured CTLs were adoptively transferred into wildtype C57BL/6NCr mice 
after stimulation with 3SI and QQ-SON treatment through intravenous injection 
through the tail vein with a volume of 300ul. Cell viability was determined using 
trypan blue and a hemocytometer. Blood was collected at various time points post 
transfer. 
Intracellular staining 
vitro cultured CTLs were stimulated in Allos with 0.2uM OVA257-264 peptide and 1ul 
Brefeldin A (Biolegend) for 3.5hours at 37 OC and 5% CO2 in order to stain cells with 
IFNγ and TNFα. Directly conjugated fluorescent antibodies were purchased from BD 
Biosciences, eBioscience, or Biolegend. Granzyme B and BCL-2, and IFNγ and 
TNFα intracellular staining all follow the next protocol. 4% Paraformalin was used to 
fix the cells for 15minutes at 4OC, then permeablized with saponin-containing 
Perm/Wash buffer (Biolegend) for 15minutes at 4OC. After 5 minutes of incubation 
with Fc blocker (CD16/32), the cells are incubated with the conjugated antibodies for 
IFNγ -PE and TNFα-APC, and GZB-PE and BCL-2 PB separately for 30min at 4OC. 
Then each sample of cells were washed with Perm/Wash buffer, followed by a wash 
with PBS with 2% FBS. These samples were then read with the FACSCanto II 






Annexin V staining 
Cells were washed twice with cold Biolegend’s Cell Staining Buffer (Cat# 420201), 
then resuspended in Annexin V Binding Buffer. Pacific Blue Annexin V monoclonal 
antibody was added followed by 10ul of Propidium Iodide Solution. The cells were 
then gently vortexed and wrapped with foil to prevent light exposure while incubating 
for 15minutes at room temperature. An additional 400ul of Annexin V Binding 
Buffer was added and read at the FACS CANTO II flow cytometer. The results were 
analyzed using Flowjo. 
CFSE staining 
Before plating, cells were washed in a large volume of HBSS then resuspended in 
5x106 cells/ml. An equal volume of HBSS was put in a second tube and both were 
warmed in a 37 OC water bath for 15minutes. 22ul of 0.09m CFSE was added to the 
second tube, then the tubes were combined together, vortexing to mix. The CFSE and 
cell mixture was then incubated for 5minutes at 37 OC, mixing three times throughout. 
The cells were quenched with 40ml of cold Allos media, and then washed with an 
additional 40ml of cold Allos media. They were then resuspended at 200,000cells/ml 
to be plated. After 2 days of antigen stimulation, the cells were stained with CD25-
APC following the Surface staining protocol. 
 
Surface staining 
For cell surface markers, the cells were washed and put in the 4OC for 5minutes with 
Fc blocker. A conjugate antibody cocktail is added to incubate in the 4OC for 





Biosciences, eBioscience, or Biolegend. Afterward, the cells were fixed with 4% 
Paraformalin for 15minutes in 4OC before being washed with PBS containing 2% 
FBS. These samples were also read with the FACSCanto II machine and analyzed 
with Flowjo.  
PCR 
RNA was extracted using RNeasy Micro Kit (Qiagen) and concentration of RNA was 
determined using NanoDrop Spectrophotometer. cDNA was synthesized from the 
RNA using QuantiTech Reverse Transcription kit (Qiagen). For regular PCR, cDNA 
was diluted 1:1 with RNase- and DNase-free water. 1ul of cDNA template was added 
to 12.5ul GoTaq Green Master Mix, 10.5ul nuclease free water, 0.5ul Forward 
primer, and 0.5ul Reverse primer. Load the PCR tubes into the thermocycler for 2min 
at 95C for initial denaturation followed by 25, 30, or 35cycles of 30sec at 95C, 30sec 
55C for annealing, and 1 minute at 72C for extension, and 5minutes at 72C for final 
extension. To determine, 10ul of this final mixture was loaded into each well in a 1% 
agarose gel with ethidium bromide along with a 1Kb DNA ladder. A Chemidoc was 
used to visualize the expression of each gene.  
Statistical analysis 
To determine significant differences between treatments, we used unpaired two-tailed 








Chapter 3: Results 
Experimental Model 
The OT-I mouse model that we used has the same genetic background as 
C57/B6 mice. Their cells are marked with a congenital marker CD45.2 so the 
transferred cells can be tracked in recipient wildtype mice. This mouse model’s T 
cells have T cell receptors that are transgenic for the OVA peptide SIINFEKL. Naïve 
CTLs were harvested and activated in vitro under the standard three signal activation 
conditions (3SI) [20]. To generate tumor-infiltrating OT-I CTLs, B6 mice, transferred 
with 2x106 naïve OT-I cells, were injected subcutaneously with EG7-OVA, a 
lymphoma transgenically expressing the OVA antigen [24, 169]. The tumor was 
harvested when the tumor reached approximately 2000mm3 about 3-4 weeks after 
inoculation. The tumor-infiltrating CD8+ T cells (TICTLs) were isolated using flow 
cytometry as described in the Methods. Naïve CD8+ T cells, as a control, were 
isolated from the lymph nodes of OT-I mice and activated in vitro [20]. 
 TICTLs as exhausted but responsive 
TICTLs showed signs of exhaustion. In comparison to effector CTLs, TICTLs 
exhibited a CD25lo, CD44med, CD62Llo phenotype and minimal IFNγ, TNFα, and 
GZB, production before 3SI stimulation (Figure 5A). TICTLs also showed decreased 
expansion after in vitro antigen stimulation compared with stimulated effector CTLs 
(Figure 5B). Before antigen stimulation, the lowered proliferation combined with the 
terminally differentiated phenotype, and the impaired production of cytolytic 





unable to control the cancer in their current state [54, 170-172]. However, after 3SI 
stimulation TICTLs did show a increase in IFNγ, TNFα, and GZB, production equal 
to that of in vitro stimulated effector CTLs, despite their lowered expansion (Figure 
5B). This indicates that TICTLs are still capable of responding to an antigen 
challenge, but only under the most optimal conditions [134, 170, 171]. The ability of 
these exhausted TICTLs to still be able to produce a cytolytic response is the reason 
that ACT is able cause tumor regression [13]. By starting off with older, exhausted 
TICTLs, ACT is limited to this terminally-differentiated phenotype that can only 
respond and kill in the short-term [13].  We aim to reinvigorate these exhausted 




















Figure 5: TICTLs are exhausted but responsive terminally differentiated CTLs: 
Naïve CTLs and isolated TICTLs were cultured under 3SI conditions for 3 days. (A) 
Fold expansion was calculated after 3 days of stimulation with 3SI (Antigen+B7+IL-
12) (B) Cytolytic and activation related molecule expression was assessed using flow 




























Concurrent QQ-SON treatment of naïve T cells 
In initial trials, QQ-SON stimulation was given concurrently with 3SI in vitro 
activation to isolated naïve CD8+ T cells for 3 days (Figure 6A). The SON stimulated 
cells exhibited similar cell proliferation, IFNγ, and GZB production and activation 
marker expression as in vitro activated CTLs without QQ-SON stimulation (Figure 
6B). However, the behavior of the in vitro activated cells in vivo was drastically 
different between those exposed to QQ-SON. After transferring an equal number of 
cells, the SON treated CD8+ T cells were unable to survive in vivo (Figure 6C and 
Figure 6D). The naïve CTLs are sensitive to SON treatment, but they do not display 
any phenotypic changes compared to in vitro activated naïve CTLs without SON 
treatment. The reaction of naïve CTLs to QQ-SON stimulation implies that, while 
most of the cytolytic machinery seems to have remained functional, SON has altered 
a survival mechanism that is necessary under in vivo conditions. It appears that SON 


















































































































































Figure 6: Concurrent treatment with QQ-SON of Naïve CTLs: OTI CD8+ T cells 
were purified and divided between two treatments. The first were exposed to only 3SI 
(antigen+ B7+ IL-12) stimulation for three days. The other combed 3SI stimulation 
with 0.5ug/ml at days 0,1, and 2. On the third day, the CD8+ T cells were harvested 
for staining (B) or injected intravenously into mice. The blood was collected from the 
mice on day 5 (C), 14 (D), and 30 after injection and stained. This was repeated three 
times 
 
48hr QQ-SON treatment 
We designed a lineage reprograming protocol based on previous CTL 
manipulations [19, 167]. In order to optimize the QQ-SON conditions, we tested both 
the naïve CTLs and the TICTLs derived from OT-I mice under two 24-hour cycles of 
QQ-SON treatment (Figure 7). Each 24-hour cycle consisted of 5 hours exposure to 
QQ-SON and 19hours of rest in QQ-free media. In order to fully reprogram somatic 
cells, cells must undergo a minimum of 2-3 cycles of QQ-SON [167]. After the SON 
cycles were completed, the cells were given an optional 48 hour rest period before 
being plated under three signal CTL activation conditions (3SI) with IL-2 for 4-5 
days. These CTL activation conditions should indicate to the partially reprogrammed 
T cells that these SON-treated cells should remain T cells. 4-5 days of 3SI allowed 
the SON-treated cells to stabilize their proliferation. The SON-treated cells were then 
transferred to an uncoated plate or T25 flask. The cells were maintained by passaging 
every 2-3 days. 
After treatment with two 24 hour cycles of QQ-SON (48 hour SON), the 
TICTLs (STICTLs) became a highly proliferative and remained so after 6 months of 
continuous passaging (Figure 8A and 8B). However, naïve CTLs treated under the 





stimulation (Data not shown). Conventionally, naïve CTLs stimulated with 3SI 
activation and without SON treatment only last for 12 days in vitro under optimal 3SI 
conditions and quickly died without antigen and cytokine stimulation (Figure 8A). 
The STICTLs also were larger in cell size than their effector control (Figure 8C). The 
STICTLs have clearly been altered by the SON treatment to increase their 
proliferation, unlike the naïve CTLs that could not survive in vitro for an extended 














Figure 7: Experiment Design of Lineage Reprogramming with QQ-SON: Naïve 
CD8+T cells were purified from OTI mice then injected into tumor bearing (EG7-
OVA) Wildtype mice (C57B6). The tumor was harvested when it reached about 
1000mm3 and the CD8+ T cells were isolated from the tumor (TICTL). TICTLs and 
in vitro activation Naïve CTLs were plated under two different conditions. They were 
exposed either one or two 24 hour cycles. Each 24 hour cycle consisted of 5 hours of 
QQ-SON exposure and 19hours of rest, with an optional 48 hour rest period. The 
cells were then plated for 4-5 days of 3SI stimulation. After this they were transferred 





















































Figure 8: STICTLs endure in vitro and in vivo while Naïve CTLs falter: Naïve 
CTLs and STICTLs were plated on 3SI stimulation for 3 days. Every 3 days the cells 
were counted (A) and replated at 3x105 cells per well with fresh media. (B) Fold 
change was calculated from the Day 3 cell counts compared to original 3x105cells 
plated to each well and 5 replicates were averaged. (C) Naïve CTLs and STICTLs 
were read using a flow cytometer (D) Wildtype mice were intravenously injected with 
2x106 STICTLs cultured in antigen-free conditions; necropsies were performed 19 
days after transfer. (E) STICTLs from unstimulated conditions were stained with liver 
associated adhesion molecules. This procedure and analysis was replicated four times 
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STICTLs proliferate in liver after transfer 
Next, we wanted to see if these SON treated TICTLs (STICTLs) behaved in 
vivo as they did in vitro. We wondered if this sustained proliferative response would 
result in the formation of a tumor. Wildtype mice were injected intravenously with 
different concentrations of STICTLs; the STICTLs were able to persist.  When 
STICTLs were injected intravenously at 2x106 or more, the persistence of the cells 
manifested as cystic masses in the livers in two out of three mice and sometimes 
exhibited partial paralysis of the hind legs (Figure 8D). A necropsy showed that all 
other tissues including the brain, spinal cord, lung, kidney, and intestines were mass 
free (Supplemental). The definitive borders of the cysts and the clear localization to 
the liver led us to believe that these masses were most likely not malignant. The cells 
isolated from the cysts displayed the similar passage survivability and proliferative 
capacity as the STICTLs (Data not shown). To determine why these STICTLs 
migrated to the liver, we examined the expression of common liver adhesion markers 
(Figure 8E). STICTLs expressed CD11a, CCR4, CD49d, and CXCR3 all of which 
support the localization to the liver.  
Unlike SON treated effector cells, these STICTLs were able to persist in vivo 
and continue to proliferate. Their behavior in vivo was very different from transferred 
effector cells. STICTLs were not detectable in the blood one day after injection (Data 
not Shown). Instead, the STICTLs localized to the liver rather than circulating around 
to secondary lymphoid tissue. The dichotomy between the persistent in vivo survival 





the SON treatment interacts very differently with the exhausted TICTLs compared to 













































Figure 9: STICTLs proliferate at a steady rate and resist apoptosis: (A) CFSE 
stained cells STICTLs and in vitro activated naïve CTLs were read on day 2 after 
plating. (B)Also after 3 days with or without in vitro 3SI stimulation, STICTLs and in 
vitro activated naïve CTLs were stained with Annexin V and Propidium Iodide. (C) 
STICTLs and in vitro activated naïve CTLs were intracellularly stained with BCL-2 
after 3 days of culture with or without 3SI stimulation. (D) 2 days after 3SI 
stimulation STICTLs display confluent coverage instead of cell aggregation. This 











STICTLs show reduced apoptosis in vitro 
We wanted to discern whether the STICTLs enhanced survival was from a 
decreased apoptotic rate or if the proliferative rate increased. CFSE labeling was used 
to determine the rate of cell division of the STICTLs and in vitro activated naïve 
CTLs. The STICTL demonstrated a similar proliferation speed as the in vitro 
activated naïve CTLs on day 2 of expansion regardless of the presence of antigen 
(Figure 9A). STICTLs were able to maintain a consistent proliferation rate compared 
to that of the naïve stimulated cells.  
To determine the percentage of the live cells that are entering the early 
apoptotic stage and if there are any late stage apoptotic cells present, we used an 
Annexin V and Propidium Iodide staining (Figure 9B). The STICTLs showed less 
than 1% of the live cell population entering into either the early or late stage of 
apoptosis, while naïve CTLs displayed almost 5% of their live cell population at peak 
expansion on day 2 of optimal 3SI stimulation (Figure 9B). STICTLs also exhibited 
an increased expression BCL-2, an anti-apoptotic oncogene related to enhanced 
survival, compared to that of effector cells (Figure 9C) [173-175]. The STICTLs 
appears to have a lower rate of apoptosis and a steady rate of proliferation compared 
to in vitro activated naïve CTLs.  
Despite exhibiting signs of increased survival and a stable proliferation rate, 
the STICTLs clearly did not react to antigen and cytokine stimulation. Instead of 
displaying the aggregate behavior characteristic of CTL activation, usually on day 2 





antigen stimulation (Figure 9D). The change in STICTL behavior from that of naïve 









































































































Figure 10: Phenotypic expression of activation and cytolytic markers in 
STICTLs: (A) Expression of phenotypic and activation markers 3 days after 3SI 
antigen stimulation. (B) Cytolytic molecule expression after 3 days of 3SI 
stimulation. (C) mRNA transcription of STICTLs under unstimulated conditions. (D) 
Tetramer binding expression after 3 days of 3SI stimulation. (E) Cytolytic molecule 
expression after 3 days of PHA or ConA cross-linking stimulation. Each experiment 























STICTLs are unable to respond to antigen stimulation 
In order to determine if the SON treatment changed the ability of STICTLs to 
respond to an antigen, we challenge the STICTLs with 3SI antigen stimulation in 
vitro for three days. The STICTLs did not exhibit any of the changes characteristic of 
CTL activation. The CD25lo, KLRG1lo, CD27med, CD44hi, CD62Lhi phenotype 
displayed by the STICTLs before antigen stimulation initially lead us to believe that 
the STICTLs were close to a central memory phenotype (Figure 10A). After antigen 
stimulation, the STICTLs remained the unchanged in their phenotypic expression and 
proliferation. The STICTLs did not up-regulate activation marker expression, such as 
CD25 and CD69, usually displayed by effector CTLs (Figure 10A). In fact, the 
STICTLs completely abolished CD8, the hallmark cell surface marker of cytotoxic T 
lymphocytes (Figure 6A) [35, 124, 176]. Furthermore, the STICTLs did not produce 
IFNγ, TNFα, or GZB, even after optimal 3SI stimulation (Figure 10B and Figure 
10C). This is contrary to the exhausted TICTLs that were exposed to antigen in vitro 
(Figure 8B). Antigen stimulation was unable to even induce the transcription of these 
cytolytic molecules in STICTLs (Figure 10D). This inability to produce effector 
molecules and no indication of activation in the face of continuous proliferation 
indicates that the STICTLs are neither a memory nor effector CTL.  Somehow, the 














Figure 11: Downstream signaling components of TCR and cytokine pathways: 
Regular PCR was run at 25, 30, or 35 cycles to visualize the differential gene 
expression in naïve CTLs, in vitro-activated naïve CTLS (Effector CTLs), and 
STICTLs from unstimulated conditions. (A) Parts at CTL activation interface (B) 
effector function intermediaries (C) Key effector function transcription factors. Each 
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Effector response is altered by SON treatment 
The arrest of activation markers in the STICTLs led us to question whether 
the cytolytic machinery was intact and capable of functioning or if SON treatment 
had completely incapacitated the effector response. First, we tested if the TCR is 
actively able to bind an MHC class I tetramer (Figure 10D) [177]. Tetramer binding 
is reliant on CD8 to adhere to the side of MHC class I of the tetramer, so the 
abolishment of CD8 expression in the STICTLs may explain the STICTLs’ inability 
to bind the tetramer (Figure 10D).  We then treated the STICTLs with PHA or ConA, 
to bypass the CD8 and other costimulatory mechanisms to see if the TCR signaling 
pathway could be jump-started (Figure 10E). PHA (phytohaemagglutinin) and ConA 
(Concanavalin A) are both plant derived lectins that are known to aggluntinate 
lymphocytes, especially T cells, thus activating them through the crosslinking of their 
TCRs without relying on the presence of CD8 [178]. PHA and ConA treated 
STICTLs continued to expand, but still failed to produce an effector response (Figure 
10E). The lack of activation markers and effector protein production from ConA or 
PHA stimulation demonstrates that the TCR has been disconnected from the 
downstream signaling components of the TCR signaling pathway. 
We looked at important components of the TCR signaling pathway on the 
RNA level using reverse transcriptase PCR (RT-PCR) (Figure 11). STICTLs did 
express a complete TCR/CD3 complex, CD28 for costimulation, and ZAP70 for 
initial signal transduction, all of which assist in initiating the TCR signaling pathway 
at the activation synapse (Figure 11A). NFKB, an essential transcription factor for the 





missing from the synapse is CD8 (Figure 11A). The lack of both CD8α and CD8β 
may inhibit the activation of LCK and further TCR signal transduction [179]. It 
appears that SON treatment kept most of the TCR signaling machinery intact, except 
for the down-regulation CD8.  
When we looked at other genes related to the effector function and T cell 
activation, we saw that STICTLs clearly do not function like 3SI effector CTLs. On 
the transcriptional level, STICTLs still expressed PD-1, an activation marker, and 
CD62L, an adhesion molecule to localize to the secondary lymphoid tissue. The 
STICTLs exhibited a decreased expression of the activation markers CD69, BCL-6, 
ID3, and BLIMP-1 (PRMD1), all of which contribute to the level of CTL activation 
and differentiation. The effector related markers, T-bet, Eomes, and STAT4, were 
undetectable in STICTLs.  
The inhibition of the effector molecule production leads us to believe that the 
SON transcription factors have essentially uncoupled these T cells from the TCR 
signaling pathway, but is appears that most of the effector machinery is intact.  
SON changed cytokine receptor expression and signaling 
Antigen stimulation, costimulation, and IL-12 act as the main survival signals 
for CTLs. The changes in the TCR signaling pathway, raises the suspicion SON 
treatment may have also changed the STICTLs cytokine signaling pathways. STAT4 
is a major player of signal transduction in the IL-12 signaling pathway. STAT4’s 
absence in STICTLs may indicate that transduction of the third signal of activation 





In addition to the presence of these three activation signals, CTLs also utilize 
the survival cytokines IL-2, for effector CTLs, and IL-7, often for memory CTLs 
[121, 180]. STICTLs exhibit a down regulation of both IL-2Rα (CD25) and IL-7Rα  
(CD127) (Figure 12A, Figure 12B and Figure 12C). STAT5 plays a role in both IL-2 
and IL-7 signaling pathways and is expressed within STICTLs, along with STAT3  
(Figure 11B)[121, 180]. The impaired expression of these cytokine receptors suggests 
that the STICTLs are also no longer reliant on IL-2 and IL-7 for continued cell 
survival. The SON treatment appears to have altered the cytokine signaling pathways 













Figure 12: Precursor markers of the T cell lineage: (A) induced pluripotent stem 
cell (iPSC) and embryonic stem cell (ESC) markers run under 35cycles of PCR in 
naïve CTLs, in vitro-activated naïve CTLS (Effector CTLs), and STICTLs from 
unstimulated conditions. (B) Common Lymphoid Progenitor (LPC) cell markers run 
at 35 cycles of PCR in naïve CTLs, in vitro-activated naïve CTLS (Effector CTLs), 
and STICTLs from unstimulated conditions. (C) Thymocyte cell markers from early 
thymocytes progenitor (ETP) though the double negative (DN) stages to Double 
positive [206] run for 35cycles of PCR in naïve CTLs, in vitro-activated naïve CTLS 
(Effector CTLs), and STICTLs from unstimulated conditions. Each gene was 
sequenced and PCR was repeated twice with similar results 
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STICTLs have not been reverted to progenitors 
The seemingly unlimited clonal expansion of STICTLs combined with the 
down regulation of CD8α and CD8β lead us to question if the SON treatment may 
have pushed the exhausted TICTLs into a phenotype more akin to a precursor cell 
instead of a stem cell-like T cell phenotype.  
First, we looked at common stem cell markers for ESCs and iPSCs [137, 167] 
(Figure 12A). STICTLs did not express SOX2, OCT4, NANOG, or ALP, which 
demonstrates STICTLs are not iPSCs. Next, we compared STICTLs to the 
lymphocyte precursor markers from T cell progenitors Lymphoid Progenitors (LPC) 
(Figure 12B) [10, 16, 162, 181]. The STICTL’s strong expression of ckit and Sca-1 
indicated that they were not LPCs. This Sca-1 expression is seen on DN thymocytes 
as well as memory T cells and could be related to the STICTLs ability to maintain a 
proliferative population [182, 183].  
Once, we established that the STICTLs are not progenitors; we began looking 
along the T cell lineage to see if the STICTLs were pushed into a thymocyte state. 
The STICTLs did still express a complete T cell receptor, so the STICTLs can still be 
identified as T cells. STICTLs were compared against each stage of T cell 
development in the thymus (Figure 12C) [16, 162, 163]. The obvious lack of CD8 
and CD4 surface expression definitively indicates that the STICTLs are not double 
positive thymocytes [184]. The high ckit expression, intermediate level of CD44, in 
addition to this abolishment of CD8 and CD4 leads us to believe that the STICTLs 







Figure 13: Cell cycling and proliferation genes expressed by STICTLs: Cell 
cycling and proliferation genes run for 35, 30, or 25 cycles using reverse transcriptase 
PCR to get a differential expression. (A) AKT related genes (B) Cell cycling related 
genes (C) C-myc related genes. Each gene was sequenced and PCR repeated twice 
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Since it is clear that the steadily proliferating STICTLs are not dependent on 
traditional antigen and cytokine signals to survive, we wondered if they were using an 
alternative proliferation pathway. Conventionally, activated CTLs use the AKT Map 
Kinase pathway to signal for proliferation after antigen stimulation [12, 185]. Using 
reverse transcriptase PCR, we looked at AKT as well as E2F1, PTEN and PI3K, and 
the inhibitory regulator of PDK1, PTEN [185]. Each of these components was 
expressed by the STICTLs (Figure 13A). The STICTLs also expressed the AKT 
alternative, AMPK (Figure 13A) [185].  
The expression of most of the cell cycling genes is not very different between 
the STICTLs and the naïve and effector CTLs (Figure 13B). However, Cyclin D1 
expression was completely abated in both naïve and effector CTLs, in sharp contrast 
against the clear positive expression in STICTLs (Figure 13B). The increased 
expression of Cyclin D1 is often associated with cancer growth [186].  
The STICTLs also expressed higher level of the proto-oncogene C-MYC 
(Figure 13C). C-MYC has been linked to cell proliferation and is related to 
uncontrolled growth [138]. Increased C-MYC expression leads to the activation of 
cyclins and may control E2F1 expression [187, 188]. E2F1 is a transcription factor 
that promotes the cell cycling progression from G1 to S phase [187, 188]. E2F1 and 
Runx1, Run2, and Runx3 are all expressed in STICTLs (Figure 13B and Figure 13C). 
The Runx family has been identified as a group of myc-collaborating genes [189].  
To see if the STICTLs possessed the capability of controlling their population 





tumor-suppressor gene inhibits the activity of CDK2, CDK4, and CDK6 which in 
turn reduces cell division [190]. When a cell enters a hypoxic environment, such as a 
tumor, HIF is stimulated through the PI3K/Akt/mTOR pathway [191]. HIF in turn 
aids in the stimulation of p53. Though p53 and HIF1α  are expressed by STICTLs, 
the proliferation appears to be unhindered (Figure 13B). The expression of p53 and 
HIF1α indicates that the STICTLs may use another the mechanism for their unlimited 
proliferation. 
Regardless, it is clear that the STICTLs are capable of proliferating seemingly 
indefinitely. While the SON treatment has uncoupled the TICTLs dependence on 
CTL activation signals to survive, the STICTLs still express the cell proliferation and 
cell cycling machinery similarly to naïve and effector CTLs, with additional 















Figure 14-Summary of STICTL pathways: Green shapes indicate positive 
expression in STICTLs. Red shapes show negative expression in STICTLs, blue 






















































































































Chapter 4: Discussion 
Only the STICTLs exhibited sustained proliferation in the absence of antigen 
or cytokine stimulation. Whether under concurrent QQ-SON or the same treatment 
conditions as the STICTLs, the naïve and effector cells could not maintain a steadily 
propagating population, the way the STICTLs did in vitro and in vivo. STICTLs 
demonstrate steady proliferation as shown by CFSE labeling. The STICTLs also 
appear to be slightly resistant to apoptosis and higher expression of BCL-2 compared 
with effector CTLs. A closer look at the proliferation pathway, we see that STICTLs 
express many of the main cell cycling components used by CTLs. Though these cell 
cycling pieces are present within the STICTLs, we cannot yet say if each one is 
functioning. In fact the STICTLs may express more cell cycling related genes, 
including Cyclin D1, than effector or naïve CTLs. Still, we do not yet know which 
alteration to the cell cycling pathway is contributing the most to the STICTL’s 
proliferation. 
In vitro, STICTLs did not need the same survival signals normally utilized by 
CTLs in order to survive. The STICTLs did not exhibit any change in response to 
antigen stimulation. When exposed to optimal in vitro antigen stimulation the 
STICTLs did not accelerate the proliferation rate, aggregate in clumps, or produce 
any effector molecules such as GZB, or IFNγ. We used cross-linking of the TCRs in 
an attempt to jumpstart the effector response, but STICTLs still remained 
unresponsive.  
We took a closer look at the components of the TCR signaling pathway and a 





STICTLs appeared to possess a complete TCR/CD3 complex as well as CD28 
costimulatory molecule. The essential downstream components of the TCR signaling 
pathway ZAP70 and NFKB were also positively expressed in the STICTLs. STICTLs 
do express PD-1, an activation marker, but it may be a remnant of the terminally 
differentiated state the TICTLs were previously in. STICTLs did not exhibit an 
increased expression of other activation markers like CD69 or CD25. Though 
STICTLs possess the necessary parts to initiate activation, STICTLs do not display 
any outward indication of being activated after optimal 3SI stimulation. The lack of 
response by the STICTLs suggests that QQ-SON treatment disengages the TCR 
signaling pathway. Whole transcriptome analysis may enable the identification of the 
mechanism of this disengagement caused by SON protein reprogramming.   
However, STICTLs exhibit changes in genes related to the effector function. 
They do not express Eomes and exhibit decreased expression of T-bet. Eomes and T-
bet are major regulators of T cell differentiation, with T-bet influencing the effector 
function and Eomes memory formation capabilities [12, 192, 193]. Eomes and T-bet 
are the transcription factors that interact with Runx3 and BLIMP-1 to induce the 
effector response [193-196]. Without adequate expression of these effector function 
regulators, the STICTLs would not mount an effector response. 
The survival signals, which are critical for effector CTLs, are dispensable for 
STICTLs. The STICTLs did not need an antigen signal or costimulation in vitro to 
initiate population expansion. STAT4, an important part of the IL-12 signaling 
pathway, is also missing from the STICTLs [22]. Because the TICTLs were reactive 





an alternative signaling pathway such as using other STAT, SON treatment has 
potentially altered the pathways of IL-12, one of the critical third signal cytokines for 
effector CTLs. STICTLs also show a down-regulation of both IL-2 and IL-7 survival 
cytokine receptors. IL-2 and IL-7 are known to enhance CTL survival [121, 180]. 
These three signals and survival cytokines are normally essential for effector CTL 
survival. The combination of these changes to the initiation of the effector function 
clearly demonstrates that the SON treatment uncoupled the survival mechanism from 
the antigen and cytokine signaling CTLs normally rely on. 
The most surprising key component missing from the TCR signaling pathway 
was CD8. On both the protein and mRNA level the expression of CD8 was abolished. 
There have been cases of a down-regulation of CD8 during the early stages of 
Listeria monocytogenes or vaccinia virus infections, but only on the protein level, 
mRNA transcription of CD8 continued [197]. The TICTLs that were treated with 
SON were isolated based on their expression of CD8, indicating that this complete 
down-regulation is the result of the SON treatment. The low transcription of CD4 
mRNA was unexpected, but the expression level is less than the residual transcription 
seen in CD8+ naïve and CD8+ effector CTLs.  
The down-regulation of these hallmark surface proteins of T cells lead us to 
question whether the SON treatment may have pushed the TICTLs into a precursor 
stage. The STICTLs do not express SOX2, OCT4, NANOG or ALP (Figure 12A), 
which are characteristics of an iPSC, so STICTLs are not iPSC. STICTLs displayed a 
low or negative expression of activation markers CD69, KLRG1, CD25, and CD127 





similar to those used to identify central memory T cells, such as a high level of CD44, 
CD62L, and low expression of CD25. However, the low expression of CCR7 and 
their inability to respond to an antigen demonstrates that the STICTLs are not central 
memory CTLs [25, 114, 198]. Compounded with an absence of the protein expression 
of both CD8 and CD4, STICTLs cannot be classified as a mature T cell or a double 
positive thymocyte. Because of this, we looked further back along the T cell lineage 
to see what the STICTLs have become.  
The markers of thymocytes stages signify that STICTLs may have settled 
within a double negative stage of development. Though the STICTLs do not express 
CD8 and CD4, they do possess a complete TCR/CD3 complex that lets us continue to 
designate these cells as T cells (Figure 11). The clear expression of ckit, CD44, and 
CD27 (Figure 12) further supports that the TICTLs were pushed too far back along 
the T cell lineage by SON to become a cell-type closer to an early double negative 
thymocytes [16, 162, 163].  
The behavior of STICTLs in vivo differed to that of than that transferred 
effector CTLs. Rather than circulating in the blood or locating to secondary lymph 
tissue, these STICTLs localize to the liver of the recipient mice, where they settle and 
continue to proliferate. We looked at common liver adhesion molecules. The 
STICTLs positively expressed CD11a along with slight expression of CCR4, 
CXCR3, and CD49d [199-204].  
When other CTLs migrate to the liver they usually follow a chemokine 
gradient and roll along the vasculature expressing adhesion receptors that allow them 





lymphocytes to their destination [199, 200]. CXCR3 encourages localization to the 
liver sinusoids and liver associated lymphocytes display an increased expression of 
CD11a, and low expression of CD49d [200, 204]. CCR4 has been noted on liver 
localizing Tregs as well [200, 201]. Terminally differentiated CTLs not specific to 
liver-related infections are believed to migrate to the liver to apoptose and be broken 
down [199, 205].  But instead of apoptosis, the STICTLs survive, possibly due to the 
alterations SON treatment has made on the STICTL survival mechanism [199, 205]. 
The enhanced survival STICTLs display both in vivo and in vitro, may be due to the 
up-regulation of certain genes related to cell cycling, such as Cyclin D1. 
Though a few of the genes expressed by STICTLs are associated with the 
unlimited growth of cancer cells, the targeted migration of the STICTLs to a 
particular organ suggests that the STICTLs have not become malignant. The clear 
borders seen on the cystic formations in the liver also suggest that the STICTLs 
simply continue proliferating in a confined space and are not actively invading the 
surrounding tissue. However, the up-regulation of genes, such as Cyclin D1 and C-
MYC, may still be related to the unlimited growth displayed by the STICTLs. 
Regardless of the functionality of these STICTLs, the transient exposure to SON has 
clearly enhanced the proliferation of the TICTLs. 
We found the effector and naïve cells react very differently than exhausted 
TICTLs to SON treatment using a nuclear protein deliver system. This difference in 
response to the master regulator SON transcription factors could be related to the 
exhausted state the antigenic experienced TICTLs faced while in the tumor. It is 





microenvironment of the tumor increased the susceptibility of the TICTLs to 
alteration by SON, while the naïve and effector CTLs remained more fixed in terms 
of their survivability.  
More investigation is needed to gain a more complete picture of how SON 
acts on the T cell genome. An in depth look at the differences between the exhausted 
TICTLs and naïve and effector CTLs may shed light on why the TICTLs were more 
receptive to SON manipulation. Other exhausted T cells created by chronic infections 
could also become more reactive to reprogramming. An aging immune system show 
signs of senescence and exhaustion, so perhaps the elderly exhausted T cells are 
susceptible to this method of reprogramming. By understanding these differences 
between the exhausted CTLs and reactive CTLs, we may be able to increase the 
efficiency of T cell reprogramming.   
It may be beneficial for future research to explore different avenues to 
reinstate the effector function of these STICTLs, possibly by treating them with 
another round of effector related transcription factors such as T-bet and Eomes. T-bet 
and Eomes are two major regulators of the effector response and their expression 
plays a big role in the CTL’s response to antigen stimulation [193, 195]. Direct 
treatment of the TICTLs with other lineage related transcription factors might also 
help to directly push them to that young intermediate stem cell-like phenotype that 
maintains the effector response to an antigen as well as an expandable population. 
Most importantly, further investigation needs to be performed to find how these three 
transcription factors acts on the T cell genome and why the exhausted TICTLs are 





In summary, treatment with the pluripotency master regulators SOX2, OCT4, 
and NANOG proteins seems to disengage the TICTLs from the normal effector 
response (Figure 14).  SON treatment also instills seemingly unlimited proliferation 
in these cells by removing the TICTLs’ reliance on  traditional CTL survival signals, 
such as antigen or cytokine stimulation. Though the TICTLs are clearly altered in 
their survival mechanism, they have not been reprogrammed into a typical stem cell 
stage. Nevertheless, we show here that tumor-infiltrating CTLs are uniquely sensitive 
to lineage programming using transcription factors delivered directly to nuclei as 
proteins. This sensitivity to protein lineage reprogramming may prove to be useful 





















Supplemental Figure: A) The cyst free spleen, heart, lung, and kidneys of a mouse 
injected intravenously with 2x106 STICTLs. B) Cyst free spleen, heart, lung, and 
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